



TFW

# CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: CHRIS MYERS

Signature: Chris Myers Date: July 23, 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Supplemental Information Disclosure Statement</b>  Address to: Commissioner of Patents, P.O. Box 1450 Alexandria, VA 22313-1450	<b>First Named Inventor</b>	<b>Dunn, James Patrick et al.</b>
	<b>Application Number</b>	<b>10/807,766</b>
	<b>Filing Date</b>	<b>03-24-2004</b>
	<b>Group Art Unit</b>	<b>TBA</b>
	<b>Examiner</b>	<b>TBA</b>
	<b>Attorney Docket No.</b>	<b>R0170B-REG</b>
	<b>Title</b>	<b>NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS</b>

Sir:

### Transmittal for Supplemental Information Disclosure Statement

Applicants wish to bring additional references which have been identified to the attention of the Examiner. The attached Information Disclosure Statement is filed in compliance with 37 CFR §1.56, and the documents cited therein may be material to the patentability of the subject patent application.

- [X] Attached are:
- Supplemental Information Disclosure Statement / Form 1449, with copy of references B4-B7 and C6-C7
  - Return postcard
- [X] The Information Disclosure Statement is being submitted (a) within three months of the filing date, or (b) before the mailing date of the first Office Action. **Therefore, no fee is due under 37 CFR 1.97(b).**
- [X] Applicants believe that no fees are due. However, should this not be the case, the Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 18-1700.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Brian L. Buckwalter", is written over a horizontal line.

By: Brian L. Buckwalter  
Registration No. 46,585  
Agent for Applicants

July 23, 2004

Roche Palo Alto LLC  
3431 Hillview Avenue,  
Palo Alto, CA 94304-1397  
Telephone 650-855-6995  
Telecopier 650-855-5322



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/807,766
Filing Date	March 23, 2004
First Named Inventor	James Patrick Dunn
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	R0170B-REG

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	A1	US 5,436,252	07-25-1995	Sorenson, et al.	
	A8	US- 5,331,002	07-19-1994	Miller, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B4	WO 98/04135-A1	02-05-1998	Bristol Myers Squibb		
	B5	WO 02/38553-A2	05-16-2002	Eli Lilly & Company		
	B6	WO 96/13264-A1	05-09-1996	Eli Lilly & Company		
	B7	EP 0 435 177-B1	07-03-1991	Dow Merrell Pharmaceuticals Inc.		

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C6	WILDER SMITH, A. E. "Preparation of some New 4-Substituted Derivatives of p-Amino-o-hydroxy-phenyl-1,3,4-oxadizolone-5 and Study of their Mycobacteriostatic properties", <i>Arzneim. Forschung</i> 1967 67(17):768-772	
	C7	YÜKSEK, H. et al. "Synthesis and Antibacterial Activities of some 4,5-Dihydro-1H-1,2,4-triazol-5-ones", <i>Arzneim. Forschung</i> 1997 47(4):405-409.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Doc. #125434